title: Glioblastoma. Part II: Future directions.
abstract: Although uncommon, "brain cancer" is one of the most feared diseases that afflict human beings. While still regarded as one of the most deadly forms of primary malignant brain neoplasm, recent advances in the treatment of Glioblastoma Multiforme (GBM) have offered new hope for patients, families and clinicians. In the first part of this two-part evidence-based review, we focused on the multidisciplinary advances that have established the current standard of care practice in the management of GBM. The second part discusses ongoing research efforts, both ongoing clinical trial efforts as well as some of the newer technologies that are forming the promise of the future.
authors: Saint Luke's Brain Tumor Center, Kansas City, Mo, USA. msalacz@saint-lukes.org
authors: Michael E
authors: ME
authors: Salacz
authors: Kenneth R
authors: KR
authors: Watson
authors: David A
authors: DA
authors: Schomas
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001812:Blood-Brain Barrier / Q000187:drug effects; D001932:Brain Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy / Q000639:trends; D005909:Glioblastoma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D007269:Injections, Intra-Arterial; D008495:Medical Oncology / Q000639:trends*; D058990:Molecular Targeted Therapy; D018787:Radiation Oncology / Q000639:trends; D059039:Standard of Care / Q000639:trends*
chemical_list: D000970:Antineoplastic Agents